Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The prostate volume is not enlarged in some patients with lower urinary tract symptoms (LUTS). Evidence shows that prostate fibrosis, in addition to BPH and smooth muscle dysfunction, is one of the causes of LUTS, and that its occurrence is related to inflammation of various causes, ischemia, hypoxia and drugs, with the differentiation, aggregation and activation of myofibroblasts involved in its pathogenesis. Therefore, anti-inflammation and anti-fibrosis strategies may be considered as potential targets for the treatment of LUTS. This article presents an overview on the causes of prostatic fibrosis, its diagnosis, its association with LUTS, and the advances in its treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dermatological impacts of urological cancer treatments.
World J Urol
August 2025
SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Urological cancers-including prostate, bladder, renal, and testicular cancers-are commonly treated with surgery, chemotherapy, radiation therapy, and immunotherapy. While these therapies improve survival outcomes, they often induce significant dermatological side effects that impair patients' quality of life and treatment adherence. This review synthesizes current literature on the prevalence, mechanisms, and psychosocial consequences of dermatological toxicities associated with urological cancer treatments.
View Article and Find Full Text PDFImmune dysregulation in the prostates of C57BL/6 mice mirrors that seen in human benign prostatic hyperplasia.
bioRxiv
August 2025
Department of Comparative Pathobiology, Purdue University, West Lafayette, IN 47907.
Benign prostatic hyperplasia (BPH) is the most common urologic disease in aging men, resulting in significant morbidity. The etiologies of BPH are unknown, though chronic prostatic inflammation is known to promote hyperplasia, fibrotic remodeling, and therapeutic resistance in BPH. BPH is highly complex and heterogeneous, presenting with varying degrees of stromal and epithelial proliferation, fibrosis, inflammation and associated lower urinary tract symptoms.
View Article and Find Full Text PDFSignal mining for non-bleeding adverse event in novel oral anticoagulants: a pharmacovigilance study based on FAERS database.
Naunyn Schmiedebergs Arch Pharmacol
August 2025
Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Novel oral anticoagulants (NOACs) are extensively utilized in clinical practice; however, their associated non-bleeding adverse reactions have not been adequately emphasized. This study is based on the FDA Adverse Event Reporting System (FAERS) database and analyzes adverse events associated with NOACs from a real-world perspective, particularly focusing on non-bleeding adverse reaction signals, to assess differences in the safety of NOACs and provide early warnings for clinical practice. This study obtained raw data from the FAERS database, ranging from July 1, 2014, to March 31, 2024.
View Article and Find Full Text PDFInsights into the molecular mechanisms underlying the function of lysyl oxidase like 1 in cancers.
PeerJ
August 2025
Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Dali University, Dali, Yunnan, China.
Cancer is one of the primary causes of human mortality and a significant barrier to increasing human life expectancy. The effective screening, early diagnosis, and treatment of cancer have long been clinical challenges, and thus new biomarkers or molecular targets must be identified to improve the diagnosis and treatment of cancer patients. Lysyl oxidase like 1 (LOXL1), a secreted copper-dependent amine oxidase, is commonly expressed in a variety of cell types.
View Article and Find Full Text PDFBeyond the Prostate: A Visionary Study on Ocular Impacts of Benign Prostatic Hyperplasia Drugs.
J Ocul Pharmacol Ther
August 2025
Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Benign prostatic hyperplasia (BPH) medications have been demonstrated in the literature to cause specific iris adverse effects. We conducted a comprehensive analysis of adverse ocular effects across various pathologies using the FDA Adverse Event Reporting System (FAERS). The FAERS pharmacovigilance database was scrutinized for ocular adverse events tied to BPH medications.
View Article and Find Full Text PDF